What Know About This Fund's Ultragenyx Purchase Move
A hedge fund made a sizable Ultragenyx purchase as the stock slipped about 30% over the prior year. This article brea...
Biotech Investing
On this Biotech Investing tag page, 5 recent articles cover innovative biotech stocks, Agios moves, Arcellx updates, Cogent Biosciences and more, giving you quick, actionable finance insights.
109 articlesInnoviva Stock Just This: Why a Fund Bought $2.5M More
A boutique fund recently boosted its Innoviva stake by $2.5 million, raising questions about the stock's modest 10% g...
(NRXP) 2026 Earnings Call: What Investors Should Watch
The (nrxp) 2026 earnings call highlights a shifting biotech landscape. This article breaks down what the results mean...
Gossamer (GOSS) 2026 Earnings Outlook and Implications
Gossamer Bio's 2026 earnings outlook centers on cash runway, pipeline progress, and strategic partnerships. This arti...
This Biotech Stock 355% Breakout: Deep Track Bets Big
A biotech stock has surged 355%, catching the eye of every investor from day traders to pension funds. A prominent he...
This Biotech 60%. Healthcare Stocks See Fresh $11M Bet
A top healthcare fund just lined up another $11 million in a biotech that’s surged 60%. We break down why the move ma...
Viking Therapeutics Takeover Target in Biotech Investing?
Investors increasingly ask whether Viking Therapeutics could become a takeover target. This article breaks down why b...
Daré (DARE) 2025 Earnings: A Clear Path for Investors
Daré (DARE) has a developing pipeline and a tight cash runway. This article breaks down what the Q4 2025 earnings cal...
Forget Moderna: This Biotech Juggernaut Is Rising Fast
A biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
Beaten-Down Biotech Just Lost a Backer — Should You Care
When a biotech firm loses a meaningful backer, investors face a pivotal moment. This guide explains what it signals, ...
BridgeBio Neutral Stance From Citi Shakes ATTR-CM Outlook
Citi initiates BridgeBio at Neutral, signaling caution on ATTR-CM growth despite a strong near-term ramp. The move ad...
Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Related Topics
#Stock Analysis (25)
#Earnings Analysis (22)
#Portfolio Management (15)
#Portfolio Strategy (13)
#Stock Market (12)
#Investing (10)
#Insider Trading (10)
#risk-management (8)
#Hedge Funds (7)
#Earnings (5)
#Healthcare Stocks (5)
#SEC Filings (5)
#Investment Strategy (4)
#Stock Market News (4)
#Small-Cap Stocks (4)